Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
135.9
USD
|
-0.75%
|
|
-3.05%
|
+7.90%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
5,924
|
7,375
|
6,716
|
6,376
|
6,455
|
7,273
|
-
|
-
|
Enterprise Value (EV)
1 |
5,326
|
6,748
|
6,138
|
6,149
|
6,601
|
7,662
|
7,595
|
7,241
|
P/E ratio
|
-26.5
x
|
-16.5
x
|
-16.9
x
|
-11
x
|
-13.3
x
|
-29.7
x
|
3,042
x
|
21.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
443
x
|
1,061
x
|
863
x
|
125
x
|
24.2
x
|
17.1
x
|
9.8
x
|
5.93
x
|
EV / Revenue
|
398
x
|
970
x
|
789
x
|
120
x
|
24.7
x
|
18
x
|
10.2
x
|
5.91
x
|
EV / EBITDA
|
-24.2
x
|
-21
x
|
-14.1
x
|
-11.3
x
|
-15.1
x
|
-25.5
x
|
-97
x
|
72.3
x
|
EV / FCF
|
-28
x
|
-23.2
x
|
-13.9
x
|
-12.1
x
|
-14.1
x
|
-43.3
x
|
130
x
|
35.3
x
|
FCF Yield
|
-3.57%
|
-4.32%
|
-7.19%
|
-8.3%
|
-7.12%
|
-2.31%
|
0.77%
|
2.84%
|
Price to Book
|
9.97
x
|
8.24
x
|
7.33
x
|
24.3
x
|
-44.1
x
|
-37.4
x
|
-707
x
|
-
|
Nbr of stocks (in thousands)
|
47,740
|
54,006
|
56,755
|
55,872
|
56,568
|
57,131
|
-
|
-
|
Reference price
2 |
124.1
|
136.6
|
118.3
|
114.1
|
114.1
|
127.3
|
127.3
|
127.3
|
Announcement Date
|
4/1/20
|
3/10/21
|
3/2/22
|
2/16/23
|
2/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
13.38
|
6.953
|
7.778
|
51.17
|
266.7
|
424.7
|
742.3
|
1,226
|
EBITDA
1 |
-220
|
-321.2
|
-436.4
|
-543.9
|
-436.6
|
-300.4
|
-78.32
|
100.1
|
EBIT
1 |
-226.7
|
-330.6
|
-451.8
|
-561.8
|
-455.5
|
-269.7
|
-41.29
|
380.2
|
Operating Margin
|
-1,695.1%
|
-4,755.07%
|
-5,808.59%
|
-1,097.85%
|
-170.79%
|
-63.5%
|
-5.56%
|
31.02%
|
Earnings before Tax (EBT)
1 |
-218.2
|
-419.2
|
-383.9
|
-577.8
|
-474.1
|
-221.9
|
20.59
|
420.4
|
Net income
1 |
-218
|
-419
|
-383.6
|
-583.2
|
-481.4
|
-235.9
|
10.33
|
352.5
|
Net margin
|
-1,630.03%
|
-6,025.53%
|
-4,931.56%
|
-1,139.63%
|
-180.51%
|
-55.55%
|
1.39%
|
28.76%
|
EPS
2 |
-4.690
|
-8.280
|
-7.000
|
-10.40
|
-8.550
|
-4.290
|
0.0418
|
5.872
|
Free Cash Flow
1 |
-190.2
|
-291.4
|
-441.4
|
-510.2
|
-469.8
|
-176.8
|
58.5
|
205.3
|
FCF margin
|
-1,421.72%
|
-4,191.11%
|
-5,674.38%
|
-996.97%
|
-176.14%
|
-41.63%
|
7.88%
|
16.75%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
205.13%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
566.38%
|
58.23%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/1/20
|
3/10/21
|
3/2/22
|
2/16/23
|
2/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
1.113
|
4.897
|
6.828
|
6.16
|
15.29
|
22.9
|
33.59
|
47.39
|
48.03
|
137.7
|
79.79
|
91.07
|
115.1
|
144.5
|
177.5
|
EBITDA
1 |
-93.15
|
-108.3
|
-123.6
|
-137.5
|
-140
|
-
|
-139.1
|
-
|
-129.7
|
-31.63
|
-75.47
|
-65.49
|
-46.73
|
-23.8
|
-
|
EBIT
1 |
-96.93
|
-112.6
|
-128
|
-141.9
|
-144.5
|
-147.4
|
-143.7
|
-140.8
|
-134.4
|
-36.61
|
-87.35
|
-73.75
|
-51.05
|
-21.12
|
10
|
Operating Margin
|
-8,709.07%
|
-2,298.98%
|
-1,875.06%
|
-2,303.46%
|
-945.09%
|
-643.72%
|
-427.77%
|
-297.17%
|
-279.82%
|
-26.59%
|
-109.48%
|
-80.98%
|
-44.36%
|
-14.62%
|
5.63%
|
Earnings before Tax (EBT)
1 |
-80.34
|
-106.2
|
-125.3
|
-81.37
|
-169.1
|
-202.1
|
-109.6
|
-121.9
|
-161.6
|
-81.09
|
-79.22
|
-67.28
|
-42.75
|
-12.35
|
22
|
Net income
1 |
-80.35
|
-106.1
|
-125.5
|
-81.32
|
-169
|
-207.4
|
-110.9
|
-121.4
|
-162.2
|
-86.88
|
-82.39
|
-70.36
|
-48.29
|
-21.11
|
17
|
Net margin
|
-7,219.05%
|
-2,165.86%
|
-1,837.99%
|
-1,320.11%
|
-1,105%
|
-905.91%
|
-330.21%
|
-256.23%
|
-337.73%
|
-63.09%
|
-103.26%
|
-77.26%
|
-41.97%
|
-14.61%
|
9.58%
|
EPS
2 |
-1.470
|
-1.870
|
-2.210
|
-1.460
|
-3.030
|
-3.700
|
-1.980
|
-2.160
|
-2.880
|
-1.540
|
-1.430
|
-1.219
|
-0.8109
|
-0.3129
|
0.3100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/2/22
|
5/11/22
|
8/10/22
|
11/2/22
|
2/16/23
|
4/27/23
|
9/5/23
|
11/7/23
|
2/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
146
|
390
|
323
|
-
|
Net Cash position
1 |
598
|
627
|
577
|
227
|
-
|
-
|
-
|
31.9
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.3345
x
|
-1.297
x
|
-4.12
x
|
-
|
Free Cash Flow
1 |
-190
|
-291
|
-441
|
-510
|
-470
|
-177
|
58.5
|
205
|
ROE (net income / shareholders' equity)
|
-49.7%
|
-58.4%
|
-44.5%
|
-102%
|
-818%
|
-
|
-
|
155%
|
ROA (Net income/ Total Assets)
|
-43.8%
|
-50.6%
|
-37.2%
|
-
|
-50.3%
|
-20.7%
|
12.5%
|
38.9%
|
Assets
1 |
497.8
|
828.3
|
1,032
|
-
|
957.7
|
1,142
|
82.9
|
907.1
|
Book Value Per Share
2 |
12.40
|
16.60
|
16.10
|
4.700
|
-2.590
|
-3.400
|
-0.1800
|
-
|
Cash Flow per Share
2 |
-3.980
|
-5.360
|
-7.630
|
-8.840
|
-8.300
|
-2.090
|
2.070
|
-
|
Capex
1 |
5.16
|
19.9
|
23.7
|
14.5
|
2.44
|
7.13
|
7
|
4.2
|
Capex / Sales
|
38.57%
|
285.63%
|
304.76%
|
28.31%
|
0.92%
|
1.68%
|
0.94%
|
0.34%
|
Announcement Date
|
4/1/20
|
3/10/21
|
3/2/22
|
2/16/23
|
2/7/24
|
-
|
-
|
-
|
Last Close Price
127.3
EUR Average target price
166.7
EUR Spread / Average Target +30.97% Consensus |
1st Jan change
|
Capi.
|
---|
| +7.90% | 7.76B | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|